Table 2: TNF-inhibitor and placebo effects
for ACR-20 scores according to the statistical random model.
|
TNF-inhibitor |
Prevalence |
95% CI |
Q-het |
Df-het |
p-value-het?? |
I2 |
|
Adalimumab |
0.267 |
0.161; 0.373 |
14.256 |
2 |
0.001 |
85.97 |
|
Certolizumab |
0.164 |
0.068; 0.260 |
16.971 |
2 |
0 |
88.22 |
|
Etanercept |
0.215 |
0.129; 0.302 |
4.125 |
2 |
0.127 |
51.52 |
|
Golimumab |
0.297 |
0.237; 0.358 |
0.656 |
1 |
0.418 |
0 |
|
Infliximab |
0.319 |
0.154; 0.485 |
10.633 |
1 |
0.001 |
90.59 |